This database contains 202 studies, archived under the term: "drug effects"
Click here to filter this large number of results.
Medication adherence and tolerability of Alzheimer’s disease medications: study protocol for a randomized controlled trial
Campbell, Noll L.,
Dexter, Paul,
Perkins, Anthony J.,
Gao, Sujuan,
Li, Lang,
Skaar, Todd C.,
Frame, Amie,
Hendrie, Hugh C.,
Callahan, Chris M.,
Boustani, Malaz A.
Background: The class of acetylcholinesterase inhibitors (ChEI), including donepezil, rivastigmine, and galantamine, have similar efficacy profiles in patients with mild to moderate Alzheimer’s disease (AD). However, few studies have evaluated adherence to these agents. We sought to prospectively capture the rates and reasons for nonadherence to ChEI and determine factors influencing tolerability and adherence.; Methods/design: […]
Memantine prevents hypoglycemia-induced decrements of the cerebral energy status in healthy subjects
Willenborg, B.,
Schmoller, A.,
Caspary, J.,
Melchert, U. H.,
Scholand-Engler, H. G.,
Jauch-Chara, K.,
Hohagen, F.,
Schweiger, U.,
Oltmanns, K. M.
Context: The risk to develop dementia is significantly increased in diabetes mellitus. Memantine, an N-methyl-D-aspartate receptor antagonist, which is clinically applied in dementia, has been shown to exert neuroprotective effects under hypoglycemic conditions in rats.; Objective: We hypothesized that memantine may prevent hypoglycemia-induced decrements in the cerebral high-energy phosphate, i.e. ATP, metabolism to exert its […]
Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer’s disease
Weiner, Michael W.,
Sadowsky, Carl,
Saxton, Judith,
Hofbauer, Robert K.,
Graham, Stephen M.,
Yu, Sung Yun,
Li, Shaoyi,
Hsu, Hai-An,
Suhy, Joyce,
Fridman, Moshe,
Perhach, James L.
Background: This study was designed to assess changes in brain volume and cognitive abilities in memantine-treated patients with Alzheimer’s disease (AD) by using an exploratory, single-arm, delayed-start design.; Methods: Cholinesterase inhibitor-treated patients with AD (N = 47; Mini-Mental State Examination score range: 15-23) were enrolled in an observational lead-in period (weeks: 1-24), followed by an […]
Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study
Beauchet, Olivier,
Launay, Cyrille P.,
Allali, Gazan,
Watfa, Gilles,
Gallouj, Karim,
Herrmann, François R.,
Annweiler, Cedric
Background: Anti-dementia drugs may improve gait performance. No comparison between acetylcholinesterase inhibitors (CEIs) and memantine-related changes in gait variability has been reported. The objectives of this study were to 1) quantify and compare the mean values and coefficients of variation (CoV) of stride time in demented patients with Alzheimer’s disease and related disorders (ADRD) before […]
Memantine for dementia in adults older than 40 years with Down’s syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial
Hanney, Marisa,
Prasher, Vee,
Williams, Nicola,
Jones, Emma L.,
Aarsland, Dag,
Corbett, Anne,
Lawrence, Dale,
Yu, Ly-Mee,
Tyrer, Stephen,
Francis, Paul T.,
Johnson, Tony,
Bullock, Roger,
Ballard, Clive
Background: Prevalence of Alzheimer’s disease in people with Down’s syndrome is very high, and many such individuals who are older than 40 years have pathological changes characteristic of Alzheimer’s disease. Evidence to support treatment with Alzheimer’s drugs is inadequate, although memantine is beneficial in transgenic mice. We aimed to assess safety and efficacy of memantine […]
Memantine and brain atrophy in Alzheimer’s disease: a 1-year randomized controlled trial
Wilkinson, David,
Fox, Nick C.,
Barkhof, Frederik,
Phul, Ravinder,
Lemming, Ole,
Scheltens, Philip
The primary objective of this study was to evaluate the rate of total brain atrophy (TBA) with serial magnetic resonance imaging (MRI), using the Brain Boundary Shift Integral (BBSI), in patients with probable Alzheimer’s disease (AD) over the course of 52 weeks of treatment with memantine or placebo. This was a multi-national, randomized, double-blind, placebo-controlled, […]
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study
Winblad, Bengt,
Andreasen, Niels,
Minthon, Lennart,
Floesser, Annette,
Imbert, Georges,
Dumortier, Thomas,
Maguire, R. Paul,
Blennow, Kaj,
Lundmark, Joens,
Staufenbiel, Matthias,
Orgogozo, Jean-Marc,
Graf, Ana
Background: Immunotherapy targeting the amyloid β (Aβ) peptide is a potential strategy to slow the progression of Alzheimer’s disease. We aimed to assess the safety and tolerability of CAD106, a novel active Aβ immunotherapy for patients with Alzheimer’s disease, designed to induce N-terminal Aβ-specific antibodies without an Aβ-specific T-cell response.; Methods: We did a phase […]
Cognitive Improvement during Treatment for Mild Alzheimer’s Disease with a Chinese Herbal Formula: A Randomized Controlled Trial
Zhang, Y.,
Lin, C.,
Zhang, L.,
Cui, Y.,
Gu, Y.,
Guo, J.,
Wu, D.,
Li, Q.,
Song, W.
OBJECTIVES: To explore the efficacy of Chinese herbal formula compared with donepezil 5 mg/day in patients with mild Alzheimer’s disease (AD). METHODS: Patients with mild AD meeting the criteria were randomized into Chinese herbal formula Yishen Huazhuo decoction (YHD) group and donepezil hydrochloride (DH) group during the 24-week trial. The outcomes were measured by ADAS-cog, […]